MDxHealth SA (MDXH)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-06. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 42/100 (MEDIUM), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 4.19% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- MDxHealth (MDXH) Stock Sees Fair Value Cut As Analysts Weigh Dilution And Execution
- MDxHealth (MDXH) Q2 2026 Earnings Call Transcript
- MDxHealth SA (MDXH) (Q2 2026) Earnings Call Highlights: Record Sequential Growth and Strategic ...
- MDxHealth SA (MDXH) Reports Q2 Loss, Beats Revenue Estimates
- Mdxhealth to Release Second Quarter 2026 Financial Results on August 13
- Mdxhealth Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
- Mdxhealth Announces Peer-Reviewed Publication of Oxford GPS-ProMPT Study in European Urology Oncology, Establishing Scientific Foundation for the Landmark GPS-ProtecT Randomized Controlled Trial
- MDxHealth SA (MDXH) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic Focus Amid ...
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for MDxHealth SA.
Full MDXH Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.